U.S.-Based Perrigo Buying Elan For $8.6 Bil, Shifting Domicile To Ireland
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. generic drugmaker Perrigo agreed to buy Irish Elan for $8.6 billion in a deal that will hand it royalty rights from multiple sclerosis drug Tysabri and tax savings from being domiciled in Ireland.